Continuous positive airway pressure (CPAP) is the first-line treatment of obstructive sleep apnea (OSA). Obstructive sleep apnea is a predictor of cardiovascular (CV) events. In this meta-analysis, we evaluated the effect of CPAP on left ventricular ejection fraction (LVEF), CV events, CV mortality, and all-cause mortality in patients with OSA. Nine articles (n = 9610 patients) were analyzed. Four different meta-analyses were performed: evaluation of LVEF, assessment of all-cause mortality, CV mortality, and CV events. Continuous positive airway pressure treatment was associated with a significant increase in LVEF (mean difference: 2.1%, 95% confidence interval [CI]: 0.8%-3.4%). There was a nonsignificant reduction in all-cause mortality (hazard ratio [HR]: 0.92, 95% CI: 0.73-1.15) but a significant reduction of 66% in the risk of CV mortality associated with the CPAP treatment (HR: 0.34, 95% CI: 0.17-0.68, P = .002). There was a nonsignificant reduction in the risk of CV events in the CPAP-treated patients (HR: 0.84, 95% CI: 0.60-1.18, P = .31). Our meta-analyses showed that CPAP treatment improves LVEF and could have a beneficial effect on CV mortality.
Brain Basics: Understanding Sleep. Office of Communications and Public Liaison, National Institute of Neurological Disorders and Stroke. Bethesda, MD: US National Institutes of Health; 2017. www.NINDS.nih.gov.
2.
TononiGCirelliC. Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. Neuron. 2014;81(1):12–34.
3.
PeppardPEYoungTPaltaMSkatrudJ. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342(19):1378–1384.
4.
DempseyJAVeaseySCMorganBJO’DonnellCP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47–112.
5.
PekerYKraicziHHednerJLöthSJohanssonABendeM. An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J. 1999;14(1):179–184.
6.
KawakamiNTakatsukaNShimizuH. Sleep disturbance and onset of type 2 diabetes. Diabetes Care. 2004;27(1):282–283.
7.
FuYXiaYYiHXuHGuanJYinS. Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea with or without continuous positive airway pressure treatment. Sleep Breath. 2016;21(1):181–189.
8.
OlsonEJMooreWRMorgenthalerTIGayPCStaatsBA. Obstructive sleep apnea-hypopnea syndrome. Mayo Clin Proc. 2003;78:1545–1552.
9.
McNicholasWTBonsigoreMR; Management Committee of ECAB. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007;29(1):156–178.
10.
PunjabiNMCaffoBSGoodwinJL. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6(8):e1000132.
11.
MarshallNSWongKKLiuPY. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep. 2008;31(8):1079–1085.
12.
GottliebDJYenokyanGNewmanAB. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352–360.
13.
HeJKrygerMHZorickFJConwayWRothT. Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest. 1988;94(1):9–14.
14.
KokkarinenJ. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med. 2011;183(7):950.
15.
BautersFRietzschelERHertegonneKBChirinosJA. The link between obstructive sleep apnea and cardiovascular disease. Curr Atheroscler Rep. 2016;18(1):1.
16.
McEvoyRDAnticNAHeeleyE. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919–931.
17.
ImadojemuVAGleesonKQuraishiSAKunselmanARSinowayLILeuenbergerUA. Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure therapy. Am J Respir Crit Care Med. 2002;165(7):950–953.
18.
BokinskyGMillerMAultKHusbandPMitchellJ.Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest. 1995;108(3):625–630.
19.
HigginsJPTGreenS.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Oxford: The Cochrane Collaboration; 2011.
20.
Manager R[Computer Program].Version 5.2. Copenhagen, Denmark: Centre TNC; 2012.
21.
HolmqvistFGuanNZhuZ. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015;169(5):647–654.e2.
22.
Campos-RodriguezFMartinez-GarciaMAde la Cruz-MoronI. Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study. Ann Intern Med. 2012;156(2):115–122.
23.
MarinJMCarrizoSJVicenteEAgustiAG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365(9464):1046–1053.
24.
AnandamAPatilMAkinnusiM. Cardiovascular mortality in obstructive sleep apnoea treated with continuous positive airway pressure or oral appliance: an observational study. Respirology. 2013;18(8):1184–1190.
25.
ParraOSánchez-ArmengolÁCapoteF. Efficacy of continuous positive airway pressure treatment on 5-year survival in patients with ischaemic stroke and obstructive sleep apnea: a randomized controlled trial. J Sleep Res. 2015;24(1):47–53.
26.
BradleyTDLoganAGKimoffRJ. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med. 2005;353(19):2025–2033.
27.
KanekoYFlorasJSUsuiK. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003;348(13):1233–1241.
28.
BouloukakiIGiannadakiKMermigkisC. Intensive versus standard follow-up to improve continuous positive airway pressure compliance. Eur Respir J. 2014;44(5):1262–1274.
29.
ArztMFlorasJSLoganAG. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients With Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation. 2007;115(25):3173–3180.
30.
ParkerJDBrooksDKozarLF. Acute and chronic effects of airway obstruction on canine left ventricular performance. Am J Respir Crit Care Med. 1999;160(6):1888–1896.
31.
TolleFAJudyWVYuPLMarkandON. Reduced stroke volume related to pleural pressure in obstructive sleep apnea. J Appl Physiol Respir Environ Exerc Physiol. 1983;55(6):1718–1724.
32.
SchneiderHSchaubCDChenCA. Neural and local effects of hypoxia on cardiovascular responses to obstructive apnea. J Appl Physiol. 2000;88(3):1093–1102.
TkacovaRRankinFFitzgeraldFSFlorasJSBradleyTD. Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Circulation. 1998;98(21):2269–2275.
35.
CioffiGRussoTEStefenelliC. Severe obstructive sleep apnea elicits concentric left ventricular geometry. J Hypertens. 2010;28(5):1074–1082.
36.
Ancoli-IsraelSKripkeDFKlauberMR. Morbidity, mortality and sleep-disordered breathing in community dwelling elderly. Sleep. 1996;19(4):277–282.
37.
MooeTFranklinKAHolmströmKRabbenTWiklundU. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med. 2001;164(10 pt 1):1910–1913.
38.
PekerYHednerJNorumJKraicziHCarlsonJ. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med. 2002;166(2):159–165.
39.
YeboahJRedlineSJohnsonC. Association between sleep apnea, snoring, incident cardiovascular events and all-cause mortality in an adult population: MESA. Atherosclerosis. 2011;219(2):963–968.
40.
YoungTFinnLPeppardPE. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31(8):1071–1078.
41.
BrooksDHornerRLKozarLFRender-TeixeiraCLPhillipsonEA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Investig. 1997;99(1):106–109.
42.
HednerJAWilcoxILaksLGrunsteinRRSullivanCE. A specific and potent pressor effect of hypoxia in patients with sleep apnea. Am Rev Respir Dis. 1992;146(5 pt 1):1240–1245.
43.
KatoMRoberts-ThomsonPPhillipsBG. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation. 2000;102(21):2607–2610.
44.
SannerBMKonermannMTepelMGroetzJMummenhoffCZidekW. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J. 2000;16(4):648–652.
45.
TahraniAAAliARaymondNT. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Critical Care Med. 2012;186(5):434–441.
46.
JelicSLedererDJAdamsT. Vascular inflammation in obesity and sleep apnea. Circulation. 2010;121(8):1014–1021.
47.
RångemarkCHednerJACarlsonJTGleerupGWintherK. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep. 1995;18(3):188–194.
48.
RobinsonGVPepperellJCSegalHCDaviesRJStradlingJR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax. 2004;59(9):777–782.
49.
ArnardottirESMackiewiczMGislasonTTeffKLPackAI. Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep. 2009;32(4):447–470.
50.
ShamsuzzamanASWinnickiMLanfranchiP. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002;105(21):2462–2464.
51.
NarkiewiczKMontanoNCogliatiCvan de BornePJDykenMESomersVK. Altered cardiovascular variability in obstructive sleep apnea. Circulation. 1998;98(11):1071–1077.
52.
FaulxMDStorfer-IsserAKirchnerHLJennyNSTracyRPRedlineS. Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep. 2007;30(7):923–929.
53.
TsioufisCThomopoulosCDimitriadisK. Association of obstructive sleep apnea with urinary albumin excretion in essential hypertension: a cross-sectional study. Am J Kidney Dis. 2008;52(2):285–293.
54.
FletcherECOrolinovaNBaderM. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol. 2002;92(2):627–633.
55.
Abdel-KaderKDoharSShahN. Resistant hypertension and obstructive sleep apnea in the setting of kidney disease. J Hypertens. 2012;30(5):960–966.
56.
Di MurroAPetramalaLCotestaD. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2010;11:165–172.
57.
GonzagaCCGaddamKKAhmedMI. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363–368.
58.
GaddamKPimentaEThomasSJ. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Human Hypertens. 2010;24(8):532–537.
59.
NodaANakataSKoikeY. Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. Hypertens Res. 2007;30(8):669–676.
